Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Gynecology & Urology Companies

Vantia Therapeutics appoints new CEO

This article was originally published in Scrip

  • Zoë Dann

Executive Summary

Vantia Therapeutics (UK) has named Andrew Crockett chief executive officer. He joined the company in 2009 as vice-president of business development from the US speciality pharma firm ZARS Pharma. Vantia, which was formed in 2008 as a spin-out of Ferring Research's small-molecule R&D, has two clinical phase products – VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea.

Table

View full table

Topics

Related Companies

Tags:
Gynecology & Urology Companies
Latest Headlines

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

See All
UsernamePublicRestriction

Register

SC009111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By